Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 22, 2017
| Tradename: | 1 |
| Applicant: | 1 |
| Ingredient: | 1 |
| Patents: | 10 |
| Formulation / Manufacturing: | see details |
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
FANAPT |
iloperidone |
TABLET;ORAL | 022192 | NDA | Novartis Pharmaceuticals Corporation | 0078-0595 | 0078-0595-20 | 60 TABLET in 1 BOTTLE (0078-0595-20) |
FANAPT |
iloperidone |
TABLET;ORAL | 022192 | NDA | Novartis Pharmaceuticals Corporation | 0078-0596 | 0078-0596-20 | 60 TABLET in 1 BOTTLE (0078-0596-20) |
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | May 6, 2009 | TE: | AB | RLD: | Yes | ||||
| Regulatory Exclusivity Expiration: | May 26, 2019 | ||||||||
| Regulatory Exclusivity Use: | INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA | ||||||||
| Patent: | ► Subscribe | Patent Expiration: | Nov 2, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6 | ||||||||
| Patent: | ► Subscribe | Patent Expiration: | Aug 31, 2030 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ||||||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-005 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-007 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | ► Subscribe | ► Subscribe | ||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,984 others who get our Drug Patent Expiration Alerts:
